IDEAYA Biosciences Reports $6.6M Collaboration Revenue and $98.5M Net Loss in Q1 2026

IDEAYA Biosciences, Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $6.6 million, a significant increase from zero revenue in the same period last year. This revenue was primarily attributed to the Servier License Agreement, which includes development and commercialization rights for the company's lead product candidate, darovasertib. Despite this revenue recognition, the company experienced a net loss of $98.5 million for the quarter, compared to a net loss of $72.2 million in the first quarter of 2025, reflecting a 37% increase in losses year-over-year.

Operating expenses for the quarter totaled $115.1 million, up from $84.4 million in the prior year, driven by a 35% increase in research and development expenses, which reached $95.7 million. This rise was largely due to increased fees paid to contract research organizations (CROs) and consultants, as well as higher personnel-related costs. General and administrative expenses also rose by 44% to $19.4 million, reflecting increased personnel costs and consulting services associated with the company's growth.

In terms of financial position, IDEAYA reported total assets of approximately $1.03 billion as of March 31, 2026, down from $1.11 billion at the end of 2025. The decrease was primarily due to a reduction in long-term marketable securities. The company's cash and cash equivalents increased to $157.5 million, up from $112.8 million at the end of 2025, indicating a strong liquidity position with total cash, cash equivalents, and marketable securities amounting to approximately $972.9 million.

Strategically, IDEAYA has made significant advancements in its clinical pipeline, which includes nine potential first-in-class product candidates. The company is focusing on darovasertib for uveal melanoma, with plans to submit a new drug application (NDA) in the second half of 2026. Additionally, IDEAYA has entered into various collaborations, including a recent agreement with AstraZeneca to evaluate IDE849 in combination with Imfinzi for small cell lung cancer. The company anticipates continued operating losses as it progresses through clinical development and seeks regulatory approvals.

Looking ahead, IDEAYA's management believes that its current cash reserves will be sufficient to fund operations for at least the next 12 months. However, the company acknowledges the need for additional capital to support ongoing development efforts and may seek to raise funds through equity or debt financing. The future financial performance will depend on the successful development and commercialization of its product candidates, as well as the ability to secure favorable financing terms.